Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.]

Recenti progressi in medicina - 1 Jun 2021

Esposito Immacolata, Calabria Silvia, Piccinni Carlo, Addesi Alice, Dondi Letizia, Ronconi Giulia, Pedrini Antonella, Maggioni Aldo Pietro, Curigliano Giuseppe, Listi Angela, Righi Luisella, Novello Silvia, Buglioni Simonetta, Ciliberto Gennaro, Pruneri Giancarlo, Martini Nello

Abstract excerpt

The gradual availability of genomic profiling tests and the "agnostic approvals" from FDA and EMA have opened the oncology mutational model phase, which complements and integrates the traditional hystological approach. The non-small-cell lung cancer (NSCLC) is characterized by many molecular alterations and represents the need of a change from the traditional diagnostic, therapeutic and organisational paradigms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Medical Oncology

Share to Mutation

Source

Identifiers

PMID: 34128934
DOI: 10.1701/3620.36025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.]PMID 34128934Read ↗

[Molecular diagnostics of lung cancer].Semantic proximity Read ↗

[Molecular diagnostics of lung cancer and its clinical relevance].Semantic proximity Read ↗

Genomic classification of lung cancer: toward a personalized treatment.Semantic proximity Read ↗

[Treatment of lung cancer guided by genomic tumour profiles].Semantic proximity Read ↗

[The tools for the governance of mutational oncology and agnostic drugs: from place in therapy to place in pathway.]Semantic proximity Read ↗

Barries in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World-Evidence ScenarioSemantic proximity Read ↗

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).Semantic proximity Read ↗

[Which platform to support a personalized lung cancer treatment?].Semantic proximity Read ↗

[Molecular testing clinical progress for EGFR mutation and ALK rearrangement of lung cancer based on the guideline from IASLC/CAP/AMP].Semantic proximity Read ↗

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.Semantic proximity Read ↗

Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.Semantic proximity Read ↗

[Genomic profiling and personalized approach, utopia or future reality? A clinical case.]Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.